In order to better manage the rare disease Myasthenia gravis, UCB and Huma have partnered to develop digital health solutions.

WhatsApp D. Pharma Group Join Now
Telegram D. Pharma Group Join Now
Telegram Group Latest Pharma Jobs Join Now
Telegram B. Pharma Group Join Now
Telegram Medicine Update Group Join Now
WhatsApp B. Pharma/ GPAT Channel Join Now

With the support of their physician, patients with the uncommon disease Myasthenia gravis (MG) can better understand and manage their condition thanks to a partnership between UCB and Huma Therapeutics (Huma), a leading global digital health company and global biopharmaceutical company. Prior to going global, the digital platform is beginning in Europe. The EU MDR Class IIb regulated Software as a Medical Device (SaMD) by Huma, the only disease-agnostic SaMD to acquire this degree of EU MDR regulatory classification to date, serves as the foundation for the technological platform. Patients will have access to MG-specific, dependable educational resources and will be able to use the MG-Activities of Daily Living Scale (MG-ADL) to report and monitor their symptoms over time. Through a web-based dashboard, these data are shared with clinicians so they can identify symptom exacerbations early and take appropriate action. Finding exacerbation triggers can let clinical decision-making be proactive, which should benefit patients. To make the most of in-person appointments, patients can obtain summary reports of their health data to discuss with their clinician.

Our approach is revolutionary because it allows us to work more cooperatively and quickly with our pharma partners to launch solutions with predictive algorithms that can significantly impact patients on an individual level. This is made possible by our new classification as Class IIb level regulation. “There has been a huge increase in drug development for rare diseases, and creating treatments for this population requires a greater degree of personalization, which is exactly what our digital health platform provides,” said Dan Vahdat, CEO and Founder of Huma. Our approach is revolutionary because, thanks to our new classification as Class IIb level regulation, we can collaborate more readily and quickly with our pharma partners to launch solutions with predictive algorithms that can significantly improve patients’ lives on an individual basis. We’re thrilled to work with UCB and be able to help patients with rare diseases once more, which is where we started when the company was established more than ten years ago.

The relationship is a component of UCB’s strategy to provide a patient-centered approach to improve the way care is provided to populations with rare diseases in a significant, concrete, and practical environment. According to Charl van Zyl, head of Europe/International Markets and executive vice president of neurology at UCB, the company strives to help people with rare diseases live as fully as possible. Myasthenia gravis symptoms can be very diverse, and each person’s experience with the condition is distinctively individualised. We think that advances in digital health solutions can provide each patient with the individualised support, knowledge, and resources they require.

“This digital solution is an important first step in demonstrating UCB’s commitment to the rare disease community,” said Colin Lake, vice president, head of digital care transformation, neurology, and head of digital rare disease at UCB. Myasthenia gravis is where we are starting, but we hope to eventually expand to other rare disorders. We are excited to collaborate with Huma because we think that strong collaborations are essential to providing patients with the best possible care across the spectrum of rare diseases.

Download Pharmacy India Mobile App from Play store for the preparation of GPAT, NIPER, Pharmacist, DI and other Pharma Exams.

Connect with Us

Click here to follow Us On Instagram

Click here to follow us on Facebook

Click here to follow us on Telegram Channel

Subscribe our Youtube Channel


Please enter your comment!
Please enter your name here